Business
Delay to Publication of Annual Report and Accounts
Trellus Health plc has announced a delay in the publication of its annual report and accounts for the year ended 31 December 2025, missing the 30 June 2026 AIM Rules deadline. The company's ordinary shares have remained suspended from trading on AIM since 8 May 2026 due to ongoing uncertainty regarding its financial position. Further announcements will be made as appropriate. Disclaimer*
About this update from Trellus Health Plc
Trellus Health plc ("Trellus Health", "Company" or "Group") Delay to Publication of Annual Report and Accounts The Board of Trellus Health plc confirms that the Company's annual report and accounts for the year ended 31 December 2025 will not be published by 30 June 2026 (the deadline under Rule 19 of the AIM Rules for Companies). The Company's ordinary shares remain suspended from trading on AIM since 8 May 2026 due to the ongoing uncertainty regarding the Company's financial position. Further announcements will be made as appropriate. Enquiries: Trellus Health plc https://trellushealth.com/ Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder Via Walbrook PR Joy Bessenger, Chief Financial Officer Singer Capital Markets (Nominated Adviser and Broker) Peter Steel / Jalini Kalaravy / Samed Ethemi Tel: +44 (0)20 7496 3000 303/ Walbrook PR Tel: +44 (0)20 7933 8780 or [email protected] Lianne Applegarth / Mob: +44 (0)7584 391 303/ Alice Woodings +44 (0)7407 804 654 About Trellus Health plc (www.trellushealth.com) Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes. Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health st...
View stock analysis, news, and events for Trellus Health Plc